Trial Profile
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Conatumumab (Primary) ; Ganitumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Cancer; Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Amgen; ImmunityBio
- 03 Feb 2021 Number of treatment arms has been increased from 2 to 4, by the addition of 2 more experimental arms namely- Ganitumab Monotherapy arm and Conatumumab + mFOLFOX6 +/- Bevacizumab arm.
- 17 Dec 2019 Planned End Date changed from 6 Nov 2019 to 31 Mar 2020.
- 17 Dec 2019 Planned primary completion date changed from 1 Sep 2019 to 31 Mar 2020.